

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 January 2015



Contents

Summary of PHARMAC decisions effective 1 January 2015	3
Ganciclovir eye gel – new listing.....	5
Mogine brand of lamotrigine	5
Epoetin brand change reminder.....	5
Zostrix / Zostrix HP supply issue.....	6
Citalopram hydrobromide supply issue update	6
Omnitrope – Brand Switch Fee and prescription co-payment.....	6
Imatinib mesilate – prescription co-payment.....	6
Reandron 1000 – listing of new presentation.....	6
News in brief	7
Tender News.....	8
Looking Forward	9
Sole Subsidised Supply Products cumulative to January 2015	10
New Listings.....	23
Changes to Restrictions, Chemical Names and Presentations	24
Changes to Subsidy and Manufacturer's Price.....	29
Delisted Items	31
Items to be Delisted	33
Index	35

Summary of PHARMAC decisions

EFFECTIVE 1 JANUARY 2015

New listings (page 23)

- Testosterone undecanoate (Reandron 1000) inj 250 mg per ml, 4 ml vial – Retail pharmacy-Specialist, Pharmacode change
- Ganciclovir (Virgan) eye gel 0.15%, 5 g OP – section 29
- Pharmacy services (BSF Omnitrope) brand switch fee – may only be claimed once per patient

Changes to restrictions, chemical names and presentation (pages 24-28)

- Dalteparin sodium (Fragmin) inj pre-filled syringes 2,500 iu per 0.2 ml, 5,000 iu per 0.2 ml, 12,500 iu per 0.5 ml, 15,000 iu per 0.6 ml and 18,000 iu per 0.72 ml, and inj graduated syringes 7,500 iu per 0.75 ml, 10,000 iu per 1 ml – amended Special Authority criteria
- Enoxaparin sodium (Clexane) inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg and 150 mg – amended Special Authority criteria
- Bisoprolol fumarate (Bosvate) tab 2.5 mg, 5 mg and 10 mg – amended chemical name
- Hydrocortisone and paraffin liquid and lanolin (DP Lotn HC) lotion 1% with paraffin liquid 15.9% and lanolin 0.6% - amended chemical name and presentation description
- Carbimazole (Neo-Mercazole) tab 5 mg – stat dispensing reinstated
- Somatropin (Omnitrope) inj 5 mg, 10 mg and 15 mg cartridges – prescription co-payment applies and addition of Brand Switch Fee
- Pramipexole hydrochloride (Rampipex) tab 0.25 mg and 1 mg – removal of S29
- Diazepam (Hospira) inj 5 mg per ml, 2 ml ampoule – amended presentation description
- Hyoscine hydrobromide (Hospira and Martindale) inj 400 mcg per ml, 1 ml ampoule – amended presentation description
- Imatinib mesilate (Imatinib-AFT) cap 100 mg and 400 mg – prescription co-payment applies
- Promethazine hydrochloride (Hospira) inj 25 mg per ml, 2 ml ampoule – amended presentation description
- Naloxone hydrochloride (Hospira) inj 400 mcg per ml, 1 ml ampoule – amended presentation description
- Desferrioxamine mesylate (Hospira) inj 500 mg vial – amended presentation description
- Standard supplements – amended Special Authority criteria
- Influenza vaccine (Fluarix and Influvac) inj 45 mcg in 0.5 ml syringe – amended restriction

Summary of PHARMAC decisions – effective 1 January 2015 (continued)

Increased subsidy (pages 29-30)

- Miconazole nitrate (Multichem) crm 2%, 15 g OP
- Diazepam (Hospira) inj 5 mg per ml, 2 ml ampoule
- Hyoscine hydrobromide (Hospira) inj 400 mcg per ml, 1 ml ampoule
- Promethazine hydrochloride (Hospira) inj 25 mg per ml, 2 ml ampoule
- Naloxone hydrochloride (Hospira) in 400 mcg per ml, 1 ml ampoule
- Desferrioxamine mesylate (Hospira) inj 500 mg vial

Decreased subsidy (pages 29-30)

- Docusate sodium cap 50 mg (Laxofast 50) and 120 mg (Laxofast 120)
- Losartan potassium (Lostaar) tab 12.5 mg, 25 mg, 50 mg and 100 mg
- Bisoprolol fumarate (Bosvate) tab 2.5 mg, 5 mg and 10 mg
- Fusidic acid (Foban) crm 2%, 15 g OP
- Amorolfine (Loceryl) nail soln 5%, 5 ml OP
- Solifenacin succinate (Vesicare) tab 5 mg and 10 mg
- Tenoxicam (Tilcotil) tab 20 mg
- Allopurinol (Apo-Allopuriol) tab 100 mg and 300 mg
- Amitriptyline (Amitrip) tab 25 mg and 50 mg

Ganciclovir eye gel – new listing

Ganciclovir 0.15% eye gel (Virgan) is being listed temporarily from 1 January 2015 to provide an alternative treatment while aciclovir 3% eye ointment (Zovirax) is out of stock. Virgan is unregistered and will be supplied under section 29 of the Medicines Act 1981. Refer to the notification letter on the PHARMAC website for details.



Mogine brand of lamotrigine

Douglas has advised that its brand of lamotrigine, Mogine, 100 mg tablets will run out of stock. There is a potential for this to impact on stock of the 50 mg tablets. We expect the stock issue to be resolved by April/May 2015. There are three other fully funded brands of lamotrigine; Lamictal, Arrow and Logem. We will inform neurologists directly and general practitioners via their electronic newsletter in the new year.

Epoetin brand change reminder

From 1 March 2015, Eprex (epoetin alfa [erythropoietin alfa]) will be the only brand of epoetin funded. NeoRecormon (epoetin beta) will be delisted from 1 March 2015.

Prescribers should now prescribe only epoetin alfa to patients requiring three months treatment to ensure patients can access funded treatment for the duration of the prescription.

Pharmacists should note that epoetin alfa cannot be substituted on a prescription for epoetin beta. Patients will need a new prescription for epoetin alfa. Prescribers should be writing prescriptions generically and in full to avoid confusion.

Wastage may be claimed for both epoetin alfa and epoetin beta.

Further information including a patient information leaflet and comparison of the syringes can be found at <http://www.pharmac.health.nz/medicines/my-medicine-has-changed/erythropoietin/>

Zostrix / Zostrix HP supply issue

AFT has advised that it is currently out of stock of Zostrix HP (capsaicin cream 0.075%) and expects to run out of stock of Zostrix (capsaicin cream 0.025%) shortly. AFT expects both to be back in stock in March 2015. Patients will need to discuss an alternative treatment with their prescriber.

Citalopram hydrobromide supply issue update

The Celapram brand, supplied by Mylan, was listed fully funded from 1 December 2014 until 31 March 2015 because of a potential supply issue with Arrow-Citalopram. Actavis has advised that Arrow-Citalopram is back in stock.

Omnitrope – Brand Switch Fee and prescription co-payment

A Brand Switch Fee will apply to dispensings of Omnitrope (somatropin) injection cartridges from 1 January 2015 until 31 March 2015. A reminder that prescription co-payment will also apply for all dispensings of somatropin from 1 January 2015.

Imatinib mesilate – prescription co-payment

A reminder that prescription co-payment will apply for all dispensings of imatinib 100 mg and 400 mg capsules from 1 January 2015.

Reandron 1000 – listing of new presentation

Bayer has advised of a change to Reandron 1000 (testosterone undecanoate) 250 mg per ml, 4 ml injection to a vial presentation to remove the risk of glass fragments when opening the ampoules. The vial presentation will be listed from 1 January 2015. The ampoule presentation will be delisted 1 July 2015.

News in brief

- The price and subsidy of **solifenacin** (Vesicare) 5 mg and 10 mg tablets will reduce from 1 January 2015.
- The price of Paracetamol + Codeine (Relieve), **paracetamol** 500 mg with **codeine** 8 mg, in the 100 tablet pack size will reduce from 1 January 2015 to match the subsidised price. This pack size will be delisted on 1 March 2015.
- Betagan (**levobunolol**) 0.25% eye drops will be delisted 1 July 2015. The supplier has discontinued this strength.
- Haloperidol** – MercuryPharma 5 mg per ml, 1 ml injection will be delisted 1 July 2015. The Serenace brand is now available.
- Stat dispensing will be reinstated for **carbimazole** (Neo-Mercazole) 5 mg tablets from 1 January 2015.
- The section 29 symbol will be removed from Ramipex (**pramipexole hydrochloride**) 0.25 mg and 1 mg tablets from 1 January 2015. The supplier now has Medsafe approval for Ramipex and supply under section 29 of the Medicines Act 1981 is no longer required.
- The Special Authority criteria for **standard supplements** will be amended from 1 January 2015 to include patients who have had a glossectomy.
- The Special Authority criteria for **dalteparin sodium** and **enoxaparin sodium** will be amended from 1 January 2015 to allow subsidy for use as bridging therapy for patients treated with dabigatran.
- m-Cefuroxime (**cefuroxime sodium**) 750 mg injection has been discontinued. It will be delisted 1 July 2015. The Zinacef brand is available from DHB hospitals.
- The supplier of Ginet 84 (**ciproterone acetate with ethinyloestradiol**) has decreased the price of the 84 tablet pack size of to match the subsidy from 1 January 2015. Ginet 84 will remain fully funded until delisting on 1 March 2015.
- Rex Medical has decreased the price of its **finasteride** to match the subsidy for Finpro. The Rex Medical brand will remain fully funded until delisting on 1 March 2015.



Tender News

Sole Subsidised Supply changes – effective 1 February 2015

Chemical Name	Presentation; Pack size	Sole Subsidised Supply brand (and supplier)
Acitretin	Cap 10 mg; 60 cap	Novatretn (Douglas)
Acitretin	Cap 25 mg; 60 cap	Novatretn (Douglas)
Amoxicillin with clavulanic acid	Tab 500 mg with clavulanic acid 125 mg; 20 tab	Augmentin (GSK)
Gliclazide	Tab 80 mg; 500 tab	Glizide (Mylan)
Granisetron	Tab 1 mg; 50 tab	Granirex (Rex Medical)
Ipratropium bromide	Aqueous nasal spray, 0.03%; 15 ml OP	Univent (Rex Medical)
Lamivudine	Tab 100 mg; 28 tab	Zeffix (GSK)
Loratadine	Oral liq 1 mg per ml; 200 ml	LoraPaed (AFT)
Omeprazole	Cap 10 mg; 90 cap	Ormezol Relief (Mylan)
Omeprazole	Cap 20 mg; 90 cap	Ormezol Relief (Mylan)
Omeprazole	Cap 40 mg; 90 cap	Ormezol Relief (Mylan)
Paracetamol	Tab 500 ml; 1,000 tab	Pharmacare (API)
Pyridoxine hydrochloride	Tab 25 mg; 90 tab	PyridoxADE (BNM)
Ranitidine	Tab 150 mg; 500 tab	Ranitidine Relief (Mylan)
Ranitidine	Tab 300 mg; 500 tab	Ranitidine Relief (Mylan)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.

Possible decisions for future implementation 1 February 2015

- Azathioprine (Azamun) tab 25 mg – new listing – Retail pharmacy-Specialist
- Clozapine (Clozaril) tab 25 mg and 100 mg – price and subsidy decrease
- Diclofenac sodium (Voltaren D) tab 50 mg dispersible – price decrease and removal of higher subsidy by endorsement
- Fentanyl (Fentanyl Sandoz) patch 12.5 mcg per hour, 25 mcg per hour, 50 mcg per hour, 75 mcg per hour and 100 mcg per hour – new listing
- Gliclazide (Glizide) tab 80 mg – Brand Switch Fee payable
- Imiquimod (Aldara and Apo-Imiquimod Cream 5%) crm 5% – Special Authority removed
- Methylphenidate hydrochloride extended-release (Ritalin LA) cap modified-release 10 mg, 20 mg, 30 mg and 40 mg – price and subsidy decrease
- Oral feed (powder) (Sustagen Hospital Formula) powder (chocolate and vanilla), 900 g OP – price increase
- Risperidone (Apo-Risperidone, Dr Reddy's Risperidone, Ridal and Risperdal) tab 0.5 mg, 1 mg, 2 mg and 4 mg – decreased subsidy
- Zoledronic acid (Zometa) inj 4 mg per 5 ml, vial – new listing, Special Authority – Retail pharmacy

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Abacavir sulphate	Tab 300 mg Oral liq 20 mg per ml	Ziagen	2017
Acarbose	Tab 50 mg and 100 mg	Accarb	2015
Acetazolamide	Tab 250 mg	Diamox	2017
Acetylcysteine	Inj 200 mg per ml, 10 ml	Martindale Acetylcysteine	2015
Aciclovir	Tab dispersible 200 mg, 400 mg & 800 mg	Lovir	2016
Adult diphtheria and tetanus	Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml	ADT Booster	2017
Alprazolam	Tab 250 mcg, 500 mcg & 1 mg	Xanax	2016
Amantadine hydrochloride	Cap 100 mg	Symmetrel	2017
Aminophylline	Inj 25 mg per ml, 10 ml ampoule	DBL Aminophylline	2017
Amiodarone hydrochloride	Inj 50 mg per ml, 3 ml ampoule	Cordarone-X	2016
Amisulpride	Oral liq 100 mg per ml Tab 100 mg, 200 mg & 400 mg	Solian	2016
Amitriptyline	Tab 10 mg	Arrow-Amitriptyline	2017
Amoxicillin	Inj 250 mg, 500 mg & 1 g vials Cap 250 mg & 500 mg	Ibiamox Apo-Amoxi	2017 2016
Amoxicillin with clavulanic acid	Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml	Augmentin Augmentin	2015
Aprepitant	Cap 2 x 80 mg and 1 x 125 mg	Emend Tri-Pack	2017
Ascorbic acid	Tab 100 mg	Cvite	2016
Aspirin	Tab 100 mg Tab dispersible 300 mg	Ethics Aspirin EC Ethics Aspirin	2016
Atenolol	Tab 50 mg & 100 mg	Mylan Atenolol	2015
Atorvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Zarator	2015
Atropine sulphate	Eye drops 1%; 15 ml OP Inj 600 mcg per ml, 1 ml ampoule	Atropt AstraZeneca	2017 2015
Azathioprine	Tab 50 mg	Azamun	2016
Azithromycin	Tab 500 mg	Apo-Azithromycin	2015
Bacillus calmette-guerin vaccine	Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent	BCG Vaccine	2017
Baclofen	Tab 10 mg	Pacifen	2016

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Bendroflumethiazide [Bendrofluazide]	Tab 2.5 mg & 5 mg	Arrow-Bendrofluazide	2017
Benzathine benzylpenicillin	Inj 1.2 mega u per 2.3 ml	Bicillin LA	2015
Benzylpenicillin sodium [Penicillin G]	Inj 600 mg (1 million units) vial	Sandoz	2017
Betahistidine dihydrochloride	Tab 16 mg	Vergo 16	2017
Betaxolol	Eye drops 0.25%, 5 ml OP Eye drops 0.5%, 5 ml OP	Betoptic S Betoptic	2017
Bezafibrate	Tab 200 mg Tab long-acting 400 mg	Bezalip Bezalip Retard	2015
Bicalutamide	Tab 50 mg	Bicalaccord	2017
Blood glucose diagnostic test meter	Meter with 50 lancets, a lancing device and 10 diagnostic test strips	CareSens N CareSens N POP CareSens II	2015
Blood glucose diagnostic test strip	Blood glucose test strips	CareSens CareSens N	2015
Boceprevir	Cap 200 mg	Victrelis	2016
Brimonidine tartrate	Eye drops 0.2%, 5 ml OP	Arrow-Brimonidine	2017
Bupropion hydrochloride	Tab modified-release 150 mg	Zyban	2016
Cabergoline	Tab 0.5 mg	Dostinex	2015
Calamine	Lotn, BP	PSM	2015
Calcitonin	Inj 100 iu per ml, 1 ml ampoule	Miacalcic	2017
Calcium carbonate	Tab 1.25 g (500 mg elemental)	Arrow-Calcium	2017
Calcium folinate	Inj 50 mg	Calcium Folinate Ebewe	2017
Candesartan	Tab 4 mg, 8 mg, 16 mg & 32 mg	Candestar	2015
Capecitabine	Tab 150 mg & 500 mg	Capecitabine Winthrop	2016
Carbomer	Ophthalmic gel 0.3%, 0.5 g	Poly-Gel	2016
Cefaclor monohydrate	Cap 250 mg Grans for oral liq 125 mg per 5 ml	Ranbaxy-Cefaclor	2016
Cefalexin monohydrate	Cap 500 mg Grans for oral liq 125 mg per 5 ml & 250 mg per 5 ml	Cephalexin ABM Cefalexin Sandoz	2016 2015
Cefazolin	Inj 500 mg & 1 g vial	AFT	2017
Ceftriaxone	Inj 500 mg & 1 g vial	Ceftriazone-AFT	2016
Chloramphenicol	Eye oint 1% Eye drops 0.5%	Chlorsig Chlorafast	2015
Chlorhexidine gluconate	Mouthwash 0.2% Handrub 1% with ethanol 70%	healthE healthE	2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Ciclopirox olamine	Nail-soln 8%	Apo-Ciclopirox	2015
Ciclosporin	Oral liq 100 mg per ml	Neoral	2015
Cilazapril	Tab 0.5 mg, 2.5 mg & 5 mg	Zapril	2016
Cilazapril with hydrochlorothiazide	Tab 5 mg with hydrochlorothiazide 12.5 mg	Apo-Cilazapril/Hydrochlorothiazide	2016
Ciprofloxacin	Tab 250 mg, 500 mg & 750 mg	Cipflox	2017
Clarithromycin	Tab 250 mg & 500 mg	Apo-Clarithromycin	2017
Clindamycin	Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml	Clindamycin ABM Dalacin C	2016
Clomiphene citrate	Tab 50 mg	Serophene	2016
Clomipramine hydrochloride	Tab 10 mg & 25 mg	Apo-Clomipramine	2015
Clonidine	Patch 2.5 mg, 100 mcg per day Patch 5 mg, 200 mcg per day Patch 7.5 mg, 300 mcg per day	Catapres TTS 1 Catapres TTS 2 Catapres TTS 3	2017
Clonidine hydrochloride	Tab 25 mcg Tab 150 mcg Inj 150 mcg per ml, 1 ml	Clonidine BNM Catapres	2015
Clopidogrel	Tab 75 mg	Arrow - Clopid	2016
Clotrimazole	Crm 1%, 20 g OP Vaginal crm 1% with applicators Vaginal crm 2% with applicators	Clomazol	2017 2016
Coal tar	Soln	Midwest	2016
Codeine phosphate	Tab 15 mg, 30 mg & 60 mg	PSM	2016
Colchicine	Tab 500 mcg	Colgout	2016
Compound electrolytes	Powder for oral soln	Enerlyte	2016
Crotamiton	Crm 10%	Itch-Soothe	2015
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2015
Cyclopentolate hydrochloride	Eye drops 1%, 15 ml OP	Cyclogyl	2017
Cyproterone acetate	Tab 50 mg & 100 mg	Siterone	2015
Dapsone	Tab 25 mg & 100 mg	Dapsone	2017
Desmopressin acetate	Nasal spray 10 mcg per dose, 6 ml OP	Desmopressin-PH&T	2017
Dexamethasone	Eye drops 0.1%, 5 ml OP Eye oint 0.1%, 3.5 g OP Tab 1 mg & 4 mg	Maxidex Douglas	2017 2015
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml & 2 ml ampoule	Dexamethasone-hameln	2016

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Dexamethasone with neomycin sulphate and polymyxin B sulphate	Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml, 5 ml OP Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g, 3.5 g OP	Maxitrol	2017
Dexamfetamine sulfate	Tab 5 mg	PSM	2015
Dextrose with electrolytes	Soln with electrolytes; 1,000 ml OP	Pedialyte-Bubblegum	2016
Diclofenac sodium	Inj 25 mg per ml, 3 ml ampoule Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Eye drops 0.1%, 5 ml OP Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg	Voltaren Voltaren Ophtha Apo-Diclo Diclax SR	2017 2015
Dihydrocodeine tartrate	Tab long-acting 60 mg	DHC Continus	2016
Diltiazem hydrochloride	Tab 30 mg & 60 mg	Dilzem	2015
Dimethicone	Crm 5% pump bottle	healthE Dimethicone 5%	2016
Diphtheria, tetanus and pertussis vaccine	Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe	Boostrix	2017
Diphtheria, tetanus, pertussis and polio vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml	Infanrix IPV	2017
Diphtheria, tetanus, pertussis, polio, hepatitis b and haemophilus influenzae type b vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-AgU polio virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe and inj 10 mcg haemophilus influenza	Infanrix-hexa	2017
Domperidone	Tab 10 mg	Prokinex	2015
Doxazosin	Tab 2 mg & 4 mg	Apo-Doxazosin	2017
Doxycycline	Tab 100 mg	Doxine	2017
Enoxaparin sodium	Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg	Clexane	2015
Entacapone	Tab 200 mg	Entapone	2015
Ergometrine maleate	Inj 500 mcg per ml, 1 ml ampoule	DBL Ergometrine	2017
Etidronate disodium	Tab 200 mg	Arrow-Etidronate	2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Ethinylestradiol	Tab 10 mcg	NZ Medical and Scientific	2015
Exemestane	Tab 25 mg	Aromasin	2017
Felodopine	Tab long-acting 2.5 mg, 5 mg & 10 mg	Plendil ER	2015
Fentanyl	Inj 50 mcg per ml, 2 ml & 10 ml	Boucher and Muir	2015
Ferrous sulphate	Oral liq 30 mg (6 mg elemental) per 1 ml	Ferodan	2016
Filgrastim	Inj 300 mcg per 0.5 ml prefilled syringe	Zarzio	31/12/15
	Inj 480 mcg per 0.5 ml prefilled syringe	Zarzio	
Flucloxacillin	Inj 250 mg vial, 500 mg vial & 1 g vial	Flucloxin	2017
	Grans for oral liq 125 mg per 5 ml	AFT	
	Grans for oral liq 250 mg per 5 ml	AFT	2015
	Cap 250 mg & 500 mg	Staphlex	
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Ozole	2017
Fluorometholone	Eye drops 0.1%	Flucon	2015
Fluorouracil sodium	Crm 5%	Efudix	2015
Fluoxetine hydrochloride	Cap 20 mg Tab dispersible 20 mg, scored	Arrow-Fluoxetine	2016
Fluticasone propionate	Metered aqueous nasal spray, 50 mcg per dose	Flixonase Hayfever & Allergy	2015
Furosemide	Tab 500 mg Tab 40 mg	Urex Forte Diurin 40	2015
Fusidic acid	Oint 2%	Foban	2016
Gemfibrozil	Tab 600 mg	Lipazil	2016
Gentamicin sulphate	Inj 40 mg per ml, 2 ml	Pfizer	2015
Glipizide	Tab 5 mg	Minidiab	2015
Glucose [dextrose]	Inj 50%, 10 ml ampoule Inj 50%, 90 ml bottle	Biomed	2017
Glycerol	Suppos 3.6 g	PSM	2015
Glyceryl trinitrate	Patch 25 mg, 5 mg per day Patch 50 mg, 10 mg per day	Nitroderm TTS 5 Nitroderm TTS 10	2017
Haemophilus influenzae type b vaccine	Inj 10 mcg vial with diluent syringe	Act-HIB	2017
Haloperidol	Tab 500 mcg, 1.5 mg & 5 mg Oral liq 2 mg per ml Inj 5 mg per ml, 1 ml	Serenace	2016
Hepatitis a vaccine	Inj 1440 ELISA units in 1 ml syringe Inj 720 ELISA units in 1 ml syringe	Havrix Havrix Junior	2017

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Hepatitis b recombinant vaccine	Inj 5 mcg per 0.5 ml vial Inj 10 mg per 1 ml vial Inj 40 mg per 1 ml vial	HBvaxPRO	2017
Human papilloma virus (6,11,16 and 18) vaccine [HPV]	Inj 120 mcg in 0.5 ml syringe	Gardasil	2017
Hydrocortisone	Powder Inj 100 mg vial Tab 5 mg & 20 mg	ABM Solu-Cortef Douglas	2017 2016 2015
Hydrocortisone acetate	Rectal foam 10%, CFC-Free (14 applications)	Colifoam	2015
Hydrocortisone and paraffin liquid and lanolin	Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%	DP Lotn HC	2017
Hydrocortisone butyrate	Lipocream 0.1% Milky emul 0.1% Oint 0.1% Scalp lotn 0.1%	Locoid Lipocream Locoid Crelo Locoid Locoid	2015
Hydroxocobalamin	Inj 1 mg per ml, 1 ml	ABM Hydroxocobalamin	2015
Hydroxychloroquine	Tab 200 mg	Plaquenil	2015
Hyoscine hydrobromide	Patch 1.5 mg	Scopoderm TTS	2016
Ibuprofen	Oral liq 20 mg per ml	Fenpaed	2016
Imatinib mesilate	Tab 100 mg	Imatinib-AFT	2017
Indapamide	Tab 2.5 mg	Dapa-Tabs	2016
Ipratropium bromide	Nebuliser soln, 250 mcg per ml, 1 ml Nebuliser soln, 250 mcg per ml, 2 ml	Univent	2016
Iron polymaltose	Inj 50 mg per ml, 2 ml ampoule	Ferrum H	2017
Isoniazid	Tab 100 mg	PSM	2015
Isosorbide mononitrate	Tab 20 mg	Ismo-20	2017
Isotretinoin	Cap 10 mg & 20 mg	Oratane	2015
Ispaghula (psyllium) husk	Powder for oral soln	Konsyl-D	2016
Itraconazole	Cap 100 mg	Itrazole	2016
Ketoconazole	Shampoo 2%	Sebizole	2017
Lactulose	Oral liq 10 g per 15 ml	Laevolac	2016
Lamivudine	Oral liq 5 mg per ml Tab 150 mg Oral liq 10 mg per ml; 240 ml OP	Zeфикс Lamivudine Alphapharm 3TC	2017 2016
Lansoprazole	Cap 15 mg & 30 mg	Solox	2015
Latanoprost	Eye drops 50 mcg per ml	Hysite	2015
Letrozole	Tab 2.5 mg	Letraccord	2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Levonorgestrel	Subdermal implant (2 x 75 mg rods) Tab 1.5 mg	Jadelle Postinor-1	31/12/17 2016
Lidocaine [lignocaine] hydrochloride	Oral (viscous) soln 2% Inj 2% ampoule, 5 ml & 20 ml	Xylocaine Viscous Lidocaine-Claris	2017 2015
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Arrow-Lisinopril	2015
Lithium carbonate	Cap 250 mg Tab 250 mg & 400 mg	Douglas Lithicarb FC	2017 2015
Lodoxamide	Eye drops 0.1%, 10 ml OP	Lomide	2017
Loperamide hydrochloride	Cap 2 mg	Diamide Relief	2016
Loratadine	Tab 10 mg	Lorafix	2016
Losartan potassium with hydrochlorothiazide	Tab 50 mg with hydrochlorothiazide 12.5 mg	Arrow-Losartan & Hydrochlorothiazide	2017
Macrogol 400 and propylene glycol	Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml	Systane Unit Dose	2016
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	Lax-Sachets	2017
Magnesium sulphate	Inj 2 mmol per ml, 5 ml ampoule	DBL	2017
Mask for spacer device	Size 2	EZ-fit Paediatric Mask	2015
Measles, mumps and rubella vaccine	Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000 TCID50 rubella vial with diluent 0.5 ml vial	M-M-R II	2017
Mebeverine hydrochloride	Tab 135 mg	Colofac	2017
Medroxyprogesterone acetate	Tab 2.5 mg, 5 mg, 10 mg & 100 mg Inj 150 mg per ml, 1 ml syringe	Provera Depo-Provera	2016
Megestrol acetate	Tab 160 mg	Apo-Megestrol	2015
Meningococcal c conjugate vaccine	Inj 10 mcg in 0.5 ml syringe	Neisvac-C	2017
Meningococcal (groups a,c,y and w-135) conjugate vaccine	Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial	Menactra	2017
Mercaptopurine	Tab 50 mg	Puri-nethol	2016
Mesalazine	Enema 1 g per 100 ml	Pentasa	2015
Metformin hydrochloride	Tab immediate-release 500 mg & 850 mg	Apotex	2015
Methadone hydrochloride	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	Biodone Biodone Forte Biodone Extra Forte	2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Methotrexate	Inj 100 mg per ml, 50 ml Tab 2.5 mg & 10 mg Inj 25 mg per ml, 2 ml & 20 ml Inj prefilled syringe 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg & 30 mg	Methotrexate Ebewe Trexate Hospira Methotrexate Sandoz	2017 2015 2016
Methylprednisolone	Tab 4 mg & 100 mg	Medrol	2015
Methylprednisolone acetate	Inj 40 mg per ml, 1 ml	Depo-Medrol	2015
Methylprednisolone acetate with lidocaine (lignocaine)	Inj 40 mg per ml with lidocaine (lignocaine) 1 ml	Depo-Medrol with Lidocaine	2015
Methylprednisolone sodium succinate	Inj 40 mg per ml, 1 ml; 62.5 mg per ml, 2 ml; 500 mg & 1 g	Solu-Medrol	2015
Metoclopramide hydrochloride	Tab 10 mg Inj 5 mg per ml, 2 ml ampoule	Metamide Pfizer	2017
Metoprolol succinate	Tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg	Metoprolol-AFT CR	2015
Metoprolol tartrate	Inj 1 mg per ml, 5 ml vial Tab 50 mg & 100 mg Tab long-acting 200 mg	Lopresor Lopresor Slow-Lopresor	2015
Mercaptopurine	Tab 50 mg	Puri-nethol	2016
Miconazole	Oral gel 20 mg per g	Decozol	2015
Miconazole nitrate	Vaginal crm 2% with applicator	Micreme	2017
Mirtazapine	Tab 30 mg & 45 mg	Avanza	2015
Mitomycin C	Inj 5 mg vial	Arrow	2016
Moclobemide	Tab 150 mg & 300 mg	Apo-Moclobemide	2015
Mometasone furoate	Crm 0.1% Oint 0.1%	m-Mometasone	2015
Morphine hydrochloride	Oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml & 10 mg per ml	RA-Morph	2015
Morphine sulphate	Inj 5 mg per ml, 1 ml ampoule Inj 10 mg per ml, 1 ml ampoule Inj 15 mg per ml, 1 ml ampoule Inj 30 mg per ml, 1 ml ampoule Cap long-acting 10 mg, 30 mg, 60 mg and 100 mg Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg	DBL Morphine Sulphate m-Eslon Arrow-Morphine LA	2017 2016
Morphine tartrate	Inj 80 mg per ml, 1.5 ml & 5 ml	Hospira	2016
Mycophenolate mofetil	Cap 250 mg Tab 500 mg	Cellcept	2016
Naltrexone hydrochloride	Tab 50 mg	Naltraccord	2016
Nadolol	Tab 40 mg & 80 mg	Apo-Nadolol	2015
Naphazoline hydrochloride	Eye drops 0.1%, 15 ml OP	Naphcon Forte	2017

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Naproxen	Tab 250 mg Tab 500 mg	Noflam 250 Noflam 500	2015
Neostigmine metilsulfate	Inj 2.5 mg per ml, 1 ml ampoule	AstraZeneca	2017
Nevirapine	Tab 200 mg	Nevirapine Alphapharm	2015
Nicotine	Patch 7 mg, 14 mg & 21 mg Lozenge 1 mg & 2 mg Gum 2 mg & 4 mg (Fruit, Classic & Mint)	Habitrol	2017
Nicotinic acid	Tab 50 mg & 500 mg	Apo-Nicotinic Acid	2017
Nifedipine	Tab long-acting 30 mg & 60 mg	Adefin XL	2017
Nitrazepam	Tab 5 mg	Nitrodos	2017
Norethisterone	Tab 350 mcg	Noriday 28	2015
Norfloxacin	Tab 400 mg	Arrow-Norfloxacin	2017
Nortriptyline hydrochloride	Tab 10 mg & 25 mg	Norpress	2016
Octreotide	Inj 50 mcg per ml, 1 ml vial Inj 100 mcg per ml, 1 ml vial Inj 500 mcg per ml, 1 ml vial	DBL	2017
Oil in water emulsion	Crm	healthE Fatty Cream	2015
Olanzapine	Tab 2.5 mg, 5 mg & 10 mg Tab orodispersible 5 mg & 10 mg	Zypine Zypine ODT	2017
Ondansetron	Tab disp 4 mg Tab disp 8 mg Tab 4 mg & 8 mg	Dr Reddy's Ondansetron Ondansetron ODT-DRLA Onrex	2017 2016
Oxazepam	Tab 10 mg & 15 mg	Ox-Pam	2017
Oxybutynin	Oral liq 5 mg per ml Tab 5 mg	Apo-Oxybutynin	2016
Oxycodone hydrochloride	Tab controlled-release 10 mg, 20 mg, 40 mg & 80 mg Inj 50 mg per ml, 1 ml Inj 10 mg per ml, 1 ml & 2 ml	Oxycodone Controlled Release Tablets (BNM) OxyNorm Oxycodone Orion	2015
Oxytocin	Inj 5 iu per ml, 1 ml ampoule Inj 10 iu per ml, 1 ml ampoule Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml	Oxytocin BNM BNM Syntometrine	2015
Pamidronate disodium	Inj 3 mg per ml, 10 ml vial Inj 6 mg per ml, 10 ml vial Inj 9 mg per ml, 10 ml vial	Pamisol	2017

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Pantoprazole	Tab EC 20 mg	Pantoprazole Actavis 20	2016
	Tab EC 40 mg	Pantoprazole Actavis 40	
Paracetamol	Oral liq 120 mg per 5 ml	Paracare	2017
	Oral liq 250 mg per 5 ml	Paracare Double Strength	2017
	Suppos 500 mg	Paracare	2015
Paraffin liquid with wool fat	Eye oint 3% with wool fat 3%; 3.5 g OP	Poly-Visc	2017
Paroxetine hydrochloride	Tab 20 mg	Loxamine	2016
Peak flow meter	Low range & normal range	Breath-Alert	2015
Pegylated interferon alfa-2a	Inj 135 mcg prefilled syringe & inj 180 mcg prefilled syringe	Pegasys	2017
	Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112	Pegasys RBV Combination Pack	
	Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168	Pegasys RBV Combination Pack	
	Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112	Pegasys RBV Combination Pack	
	Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168	Pegasys RBV Combination Pack	
Perindopril	Tab 2 mg & 4 mg	Apo-Perindopril	2017
Permethrin	Lotn 5%, 30 ml OP	A-Scabies	2017
Pethidine hydrochloride	Inj 50 mg per ml, 1 ml & 2 ml	DBL Pethidine Hydrochloride PSM	2017
	Tab 50 mg & 100 mg		2015
Phenobarbitone	Tab 15 mg & 30 mg	PSM	2015
Phenoxyethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml & 250 mg per 5 ml	AFT	2016
Pilocarpine hydrochloride	Eye drops 1%; 15 ml OP Eye drops 2%; 15 ml OP Eye drops 4%; 15 ml OP	Isopto Carpine	2017
Pindolol	Tab 5 mg, 10 mg & 15 mg	Apo-Pindolol	2016
Pioglitazone	Tab 15 mg, 30 mg & 45 mg	Pizaccord	2015
Pizotifen	Tab 500 mcg	Sandomigran	2015
Pneumococcal (PCV13) vaccine	Inj 30.8 mcg in 0.5 ml syringe	Prevenar 13	2017
Pneumococcal (PPV23) polysaccharide vaccine	Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal serotype)	Pneumovax 23	2017

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Poliomyelitis vaccine	Inj 80D antigen units in 0.5 ml syringe	IPOL	2017
Poloxamer	Oral drops 10%, 30 ml OP	Coloxyl	2017
Potassium chloride	Tab long-acting 600 mg	Span-K	2015
Pramipexole hydrochloride	Tab 0.25 mg & 1 mg	Ramipex	2016
Pravastatin	Tab 20 mg & 40 mg	Cholvastin	2017
Procaine penicillin	Inj 1.5 g in 3.4 ml syringe	Cilicaine	2017
Prochlorperazine	Tab 5 mg	Antinaus	2017
Promethazine hydrochloride	Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg	Allersoothe	2015
Pyridoxine hydrochloride	Tab 50 mg	Apo-Pyridoxine	2017
Quetiapine	Tab 25 mg, 100 mg, 200 mg & 300 mg	Quetapel	2017
Quinapril	Tab 5 mg, 10 mg & 20 mg	Arrow-Quinapril	2015
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 10 Accuretic 20	2015
Ranitidine	Oral liq 150 mg per 10 ml	Peptisoothe	2017
Rifabutin	Cap 150 mg	Mycobutin	2016
Rifampicin	Cap 150 mg & 300 mg Tab 600 mg Oral liq 100 mg per 5 ml	Rifadin	2017
Rifaximin	Tab 550 mg	Xifaxan	2017
Risperidone	Oral liq 1 mg per ml	Risperon	2017
Ritonavir	Tab 100 mg	Norvir	2015
Rizatriptan	Tab orodispersible 10 mg	Rizamelt	2017
Ropinirole hydrochloride	Tab 0.25 mg, 1 mg, 2 mg and 5 mg	Apo-Ropinirole	2016
Rotavirus live reassortant oral vaccine	Oral susp G1, G2, G3, G4, P1(8) 11.5 million CCID50	RotaTeq	2017
Roxithromycin	Tab 150 mg & 300 mg	Arrow-Roxithromycin	2015
Salbutamol	Oral liq 400 mcg per ml Nebuliser soln, 1 mg per ml & 2 mg per ml, 2.5 ml	Ventolin Asthalin	2016 2015
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml	Duolin	2015
Sertraline	Tab 50 mg & 100 mg	Arrow-Sertraline	2016

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Simvastatin	Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg	Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg	2017
Sodium chloride	Inj 23.4%, 20 ml ampoule	Biomed	2016
Sodium citrate with sodium lauryl sulphoacetate	Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	Micolette	2016
Sodium hyaluronate	Eye drops 1 mg per ml, 10 ml OP	Hylo-Fresh	2016
Somatropin	Inj cartridges 5 mg, 10 mg & 15 mg	Omnitrope	31/12/17
Spacer device	800 ml 230 ml (single patient)	Volumatic Space Chamber Plus	2015
Spiromolactone	Tab 25 mg & 100 mg	Spiractin	2016
Sulphasalazine	Tab 500 mg Tab EC 500 mg	Salazopyrin Salazopyrin EN	2016
Sumatriptan	Tab 50 mg & 100 mg Inj 12 mg per ml, 0.5 ml cartridge	Arrow-Sumatriptan	2016
Tacrolimus	Cap 0.5 mg, 1 mg & 5 mg	Tacrolimus Sandoz	31/10/18
Tamsulosin hydrochloride	Cap 400 mcg	Tamsulosin-Rex	2016
Temazepam	Tab 10 mg	Normison	2017
Temozolomide	Cap 5 mg, 20 mg, 100 mg & 250 mg	Temaccord	2016
Terazosin	Tab 1 mg, 2 mg & 5 mg	Arrow	2016
Terbinafine	Tab 250 mg	Dr Reddy's Terbinafine	2017
Testosterone cypionate	Inj 100 mg per ml, 10 ml vial	Depo-Testosterone	2017
Testosterone undecanoate	Cap 40 mg	Andriol Testocaps	2015
Tetrabenazine	Tab 25 mg	Motetis	2016
Timolol	Eye drops 0.25%, 5 ml OP Eye drops 0.5%, 5 ml OP Eye drops 0.25%, gel forming; 2.5 ml OP & eye drops 0.5%, gel forming; 2.5 ml OP	Arrow-Timolol Timoptol XE	2017 2016
Tobramycin	Eye drops 0.3%, 5 ml OP Eye oint 0.3%, 3.5 g OP	Tobrex	2017
Tramadol hydrchloride	Cap 50 mg Tab sustained-release 100 mg Tab sustained-release 150 mg Tab sustained-release 200 mg	Arrow-Tramadol Tramal SR 100 Tramal SR 150 Tramal SR 200	2017
Tranexamic acid	Tab 500 mg	Cyklokron	2016
Tretinoin	Crm 0.5 mg per g	ReTrieve	2016
Tropicamide	Eye drops 0.5%, 15 ml OP Eye drops 1%, 15 ml OP	Mydriacyl	2017

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2015

Generic Name	Presentation	Brand Name	Expiry Date*
Urea	Crm 10%	healthE Urea Cream	2016
Ursodeoxycholic acid	Cap 250 mg	Ursosan	2017
Vancomycin	Inj 500 mg	Mylan	2017
Varicella vaccine [chicken pox vaccine]	Inj 2,000 PFU vial with diluent	Varilix	2017
Verapamil hydrochloride	Tab 80 mg	Isoptin	2017
Vitamin B complex	Tab, strong, BPC	Bplex	2016
Vitamins	Tab (BCP cap strength)	Mvite	2016
Zidovudine [AZT]	Cap 100 mg Oral liq 10 mg per ml	Retrovir	2016
Zidovudine [AZT] with lamivudine	Tab 300 mg with lamivudine 150 mg	Alphapharm	2017

January changes are in bold type

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
 fully subsidised

New Listings

Effective 1 January 2015

83	TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist Inj 250 mg per ml, 4 ml vial	86.00	1	<input checked="" type="checkbox"/> Reandron 1000
Note – this is a presentation change from an ampoule to a vial.				
203	GANCICLOVIR Eye gel 0.15%	37.53	5 g OP	<input checked="" type="checkbox"/> Virgan \$29
207	PHARMACY SERVICES – May only be claimed once per patient. * Brand switch fee	4.33	1 fee	<input checked="" type="checkbox"/> BSF Omnitrope
	a) The Pharmacode for BSF Omnitrope is 2472198			

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per
✓ fully subsidised

Changes to Restrictions, Chemical Names and Presentations

Effective 1 January 2015

48 DALTEPARIN SODIUM – Special Authority see SA1270 – Retail pharmacy

Inj 2,500 iu per 0.2 ml prefilled syringe	19.97	10	✓ Fragmin
Inj 5,000 iu per 0.2 ml prefilled syringe	39.94	10	✓ Fragmin
Inj 7,500 iu per 0.75 ml graduated syringe	60.03	10	✓ Fragmin
Inj 10,000 iu per 1 ml graduated syringe	77.55	10	✓ Fragmin
Inj 12,500 iu per 0.5 ml prefilled syringe	99.96	10	✓ Fragmin
Inj 15,000 iu per 0.6 ml prefilled syringe	120.05	10	✓ Fragmin
Inj 18,000 iu per 0.72 ml prefilled syringe	158.47	10	✓ Fragmin

► SA1270 Special Authority for Subsidy

Initial application – (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application – (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal – (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal – (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner.

Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

49 ENOXAPARIN SODIUM – Special Authority see SA1174 – Retail pharmacy

Inj 20 mg	37.24	10	✓ Clexane
Inj 40 mg	49.69	10	✓ Clexane
Inj 60 mg	74.91	10	✓ Clexane
Inj 80 mg	99.86	10	✓ Clexane
Inj 100 mg	125.06	10	✓ Clexane
Inj 120 mg	155.40	10	✓ Clexane
Inj 150 mg	177.60	10	✓ Clexane

► SA1174 Special Authority for Subsidy

Initial application – (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

continued...

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$
Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 January 2015 (continued)

continued...

Initial application – (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal – (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal – (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner.

Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

56	BISOPROLOL FUMARATE					
	Tab 2.5 mg	2.40	30	✓ Bosvate		
	Tab 5 mg	3.50	30	✓ Bosvate		
	Tab 10 mg	6.40	30	✓ Bosvate		
68	HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN WITH WOOL FAT AND MINERAL OIL					
	Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% wool fat hydros 3% and mineral oil – Only on a prescription	10.57	250 ml	✓ DP Lotn HC		
86	CARBIMAZOLE (stat dispensing reinstated)					
	* Tab 5 mg	10.80	100	✓ Neo-Mercazole		
87	SOMATROPIN (OMNITROPE) – Special Authority see SA1451 – Retail pharmacy No patient co-payment payable Brand switch fee payable (Pharmacode 2472198)					
	* Inj 5 mg cartridge	109.50	1	✓ Omnitrope		
	* Inj 10 mg cartridge	219.00	1	✓ Omnitrope		
	* Inj 15 mg cartridge	328.50	1	✓ Omnitrope		
127	PRAMIPEXOLE HYDROCHLORIDE (removal of S29)					
	▲ Tab 0.25 mg	7.20	100	✓ Ramipex	<small>→ S29</small>	
	▲ Tab 1 mg	24.39	100	✓ Ramipex	<small>→ S29</small>	
136	DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency (amended presentation description)					
	Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement.....	11.83	5	✓ Hospira		
	a) Up to 5 inj available on a PSO					
	b) Only on a PSO					
	c) PSO must be endorsed "not for anaesthetic procedures".					

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	---

Changes to Restrictions – effective 1 January 2015 (continued)

141	HYOSCINE HYDROBROMIDE (amended presentation description) * Inj 400 mcg per ml, 1 ml ampoule	46.50 13.32	5 10	✓ Hospira ✓ Martindale S29
171	IMATINIB MESILATE (co-payment payable) Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule. * Cap 100 mg — No patient co-payment payable 298.90 * Cap 400 mg — No patient co-payment payable 597.80	60 30	5 10	✓ Imatinib-AFT ✓ Imatinib-AFT
197	PROMETHAZINE HYDROCHLORIDE (amended presentation description) * Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	11.99	5	✓ Hospira
207	NALOXONE HYDROCHLORIDE (amended presentation description) a) Up to 5 inj available on a PSO b) Only on a PSO * Inj 400 mcg per ml, 1 ml ampoule	48.84	5	✓ Hospira
208	DESFERRIOXAMINE MESYLATE (amended presentation description) * Inj 500 mg vial	109.89	10	✓ Hospira
225	STANDARD SUPPLEMENTS (amended criterion only displayed) ► SA1228 Special Authority for Subsidy Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or 2 Malignancy and is considered likely to develop malnutrition as a result; or 3 Is undergoing a bone marrow transplant; or 4 Tempomandibular surgery or glossectomy ; or 5 Both: 5.1 Pregnant; and 5.2 Any of the following: 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre pregnancy weight; or 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met. Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 Is being fed via a nasogastric tube; or			

continued...

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
 fully subsidised

Changes to Restrictions – effective 1 January 2015 (continued)

continued...

- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery **or glossectomy**; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

249 INFLUENZA VACCINE – [Xpharm]

Inj 45 mcg in 0.5 ml syringe 90.00 10 Fluarix
 Influvac

A) is available each year for patients who meet the following criteria, as set by PHARMAC:

- a) all people 65 years of age and over;
- b) people under 65 years of age who:
 - i) have any of the following cardiovascular disease:
 - a) ischaemic heart disease,
 - b) congestive heart disease,
 - c) rheumatic heart disease,
 - d) congenital heart disease, or
 - e) cerebo-vascular disease;
 - ii) have either of the following chronic respiratory disease:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function;
 - iii) have diabetes;
 - iv) have chronic renal disease;
 - v) have any cancer, excluding basal and squamous skin cancers if not invasive;
 - vi) have any of the following other conditions:
 - a) autoimmune disease,
 - b) immune suppression,
 - c) HIV,
 - d) transplant recipients,
 - e) neuromuscular and CNS diseases,
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - vii) are pregnant
- e) people under 18 years of age living within the boundaries of the Canterbury District Health Board.
- cd) children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
 - b) hypertension and/or dyslipidaemia without evidence of end-organ disease,
- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price)	\$	Per	Brand or Generic Mnfr
				✓ fully subsidised

Changes to Restrictions – effective 1 January 2015 (continued)

continued...

- C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor.
- D) Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year.

Effective 1 December 2014

134	CITALOPRAM HYDROBROMIDE (stat reinstated) * Tab 20 mg	2.34	84	✓ Arrow-Citalopram
-----	--	------	----	---------------------------

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
 fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 January 2015

38	DOCUSATE SODIUM – Only on a prescription (↓ subsidy)				
	* Cap 50 mg	2.31	100	<input checked="" type="checkbox"/>	Laxofast 50
	* Cap 120 mg	3.13	100	<input checked="" type="checkbox"/>	Laxofast 120
55	LOSARTAN POTASSIUM (↓ subsidy)				
	* Tab 12.5 mg	1.66 (2.88)	90		Lostaar
	* Tab 25 mg	2.04 (3.20)	90		Lostaar
	* Tab 50 mg	2.41 (5.22)	90		Lostaar
	* Tab 100 mg	2.79	90	<input checked="" type="checkbox"/>	Lostaar
56	BISOPROLOL FUMARATE (↓ subsidy)				
	Tab 2.5 mg	2.40	30	<input checked="" type="checkbox"/>	Bosvate
	Tab 5 mg	3.50	30	<input checked="" type="checkbox"/>	Bosvate
	Tab 10 mg	6.40	30	<input checked="" type="checkbox"/>	Bosvate
66	FUSIDIC ACID (↓ subsidy)				
	Crm 2%	2.52 (3.25)	15 g OP		Foban
	a) Maximum of 15 g per prescription				
	b) Only on a prescription				
	c) Not in combination				
66	AMOROLFINE (↓ subsidy)				
	a) Only on a prescription				
	b) Not in combination				
	Nail soln 5%	19.95 (61.87)	5 ml OP		Loceryl
67	MICONAZOLE NITRATE (↑ subsidy)				
	* Crm 2%	0.55	15 g OP	<input checked="" type="checkbox"/>	Multichem
	a) Only on a prescription				
	b) Not in combination				
77	ETHINYLOESTRADIOL WITH DESOGESTREL (↑ price)				
	* Tab 20 mcg with desogestrel 150 mcg and 7 inert tab	6.62 (19.80)	84		Mercilon 28
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500				
	b) Up to 84 tab available on a PSO				
	* Tab 30 mcg with desogestrel 150 mcg and 7 inert tab	6.62 (19.80)	84		Marvelon 28
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500				
	b) Up to 84 tab available on a PSO				

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	---

Changes to Subsidy and Manufacturer's Price – effective 1 January 2015 (continued)

79	CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL (↓ price) * Tab 2 mg with ethynodiol dienoate 35 mcg and 7 inert tabs – Up to 168 tab available on a PSO.....	2.68	84	✓ Ginet 84
80	FINASTERIDE – Special Authority see SA0928 – Retail pharmacy (↓ price) * Tab 5 mg	2.09	30	✓ Rex Medical
81	SOLIFENACIN SUCCINATE – Special Authority see SA0998 – Retail pharmacy (↓ subsidy) Tab 5 mg	37.50	30	✓ Vesicare
	Tab 10 mg	37.50	30	✓ Vesicare
118	TENOXICAM (↓ subsidy) * Tab 20 mg	15.25	100	✓ Tilcotil
125	ALLOPURINOL (↓ subsidy) * Tab 100 mg	15.11	1,000	✓ Apo-Allopurinol
	* Tab 300 mg – For allopurinol oral liquid formulation refer	15.91	500	✓ Apo-Allopurinol
132	PARACETAMOL WITH CODEINE – Safety medicine; prescriber may determine dispensing frequency (↓ price) * Tab paracetamol 500 mg with codeine phosphate 8 mg	2.11	100	✓ Paracetamol + Codeine (Relieve)
133	AMITRIPTYLINE – Safety medicine; prescriber may determine dispensing frequency (↓ subsidy) Tab 25 mg	1.68	100	✓ Amitrip
	Tab 50 mg	2.82	100	✓ Amitrip
136	DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency (↑ subsidy) Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement	11.83	5	✓ Hospira
	a) Up to 5 inj available on a PSO			
	b) Only on a PSO			
	c) PSO must be endorsed "not for anaesthetic procedures".			
141	HYOSCINE HYDROBROMIDE (↑ subsidy) * Inj 400 mcg per ml, 1 ml ampoule	46.50	5	✓ Hospira
197	PROMETHAZINE HYDROCHLORIDE (↑ subsidy) * Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	11.99	5	✓ Hospira
204	DORZOLAMIDE HYDROCHLORIDE (↑ price) * Eye drops 2%	9.77 (17.44)	5 ml OP	Trusopt
207	NALOXONE HYDROCHLORIDE (↑ subsidy) a) Up to 5 inj available on a PSO b) Only on a PSO * Inj 400 mcg per ml, 1 ml ampoule	48.84	5	✓ Hospira
208	DESFERRIOXAMINE MESYLATE (↑ subsidy) * Inj 500 mg vial	109.89	10	✓ Hospira

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	---

Delisted Items

Effective 1 January 2015

39	DANTHRON WITH POLOXAMER – Only on a prescription Note: Only for the prevention or treatment of constipation in the terminally ill. Oral liq 75 mg with poloxamer 1 g per 5 ml	43.60	300 ml	✓ Pinorax Forte
43	MAGNESIUM SULPHATE * Inj 2 mmol per ml, 5 ml ampoule	12.65 (18.35)	10	Martindale
47	OCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xpharm] For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Inj 250 iu vial	250.00	1	✓ Kogenate FS Note – This applies to Pharmacode 2187159 only. Pharmacode 2461366 remains listed.
54	PERINDOPRIL * Tab 2 mg	3.75 (18.50)	30	Coversyl
	* Tab 4 mg	4.80 (25.00)	30	Coversyl
69	BETAMETHASONE VALERATE WITH CLIQUINOL – Only on a prescription Oint 0.1% with clioquinol 3%	3.49 (4.90)	15 g OP	Betnovate-C
87	SOMATROPIN (GENOTROPIN) – Special Authority see SA1279 – [Xpharm] * Inj cartridge 16 iu (5.3 mg)	160.00	1	✓ Genotropin
	* Inj cartridge 36 iu (12 mg)	360.00	1	✓ Genotropin
127	PRAMIPEXOLE HYDROCHLORIDE ▲ Tab 0.125 mg	1.95	30	✓ Dr Reddy's Pramipexole
	▲ Tab 0.25 mg	2.16 (2.40)	30	Dr Reddy's Pramipexole
	▲ Tab 0.5 mg	4.20	30	✓ Dr Reddy's Pramipexole
	▲ Tab 1 mg	7.20	30	✓ Dr Reddy's Pramipexole
130	PARACETAMOL *‡ Oral liq 120 mg per 5 ml	2.08	500 ml	✓ Ethics Paracetamol a) Up to 200 ml available on a PSO b) Not in combination

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items – effective 1 January 2015 (continued)

132	OXYCODONE HYDROCHLORIDE					
	a) Only on a controlled drug form					
	b) No patient co-payment payable					
	c) Safety medicine; prescriber may determine dispensing frequency					
	Tab controlled-release 80 mg	34.00	20			✓ Oxydone BNM
134	SERTRALINE					
	* Tab 50 mg	4.42	30			✓ Zoloft
	* Tab 100 mg	4.42	30			✓ Zoloft
228	ORAL FEED (POWDER) – Special Authority see SA1228 – Hospital pharmacy [HP3]					
	Powder (vanilla)	9.50	900 g OP			✓ Fortisip

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$
Per

Brand or
Generic Mnfr
 fully subsidised

Items to be Delisted

Effective 1 April 2015

38	DOCUSATE SODIUM – Only on a prescription					
	* Cap 50 mg	2.31	100	<input checked="" type="checkbox"/>	Laxofast 50	
	* Cap 120 mg	3.13	100	<input checked="" type="checkbox"/>	Laxofast 120	
55	LOSARTAN POTASSIUM					
	* Tab 12.5 mg	1.66 (2.88)	90		Lostaar	
	* Tab 25 mg	2.04 (3.20)	90		Lostaar	
	* Tab 50 mg	2.41 (5.22)	90		Lostaar	
	* Tab 100 mg	2.79	90	<input checked="" type="checkbox"/>	Lostaar	
66	FUSIDIC ACID					
	Crm 2%	2.52 (3.25)	15 g OP		Foban	
	a) Maximum of 15 g per prescription					
	b) Only on a prescription					
	c) Not in combination					
66	AMOROLFINE					
	a) Only on a prescription					
	b) Not in combination					
	Nail soln 5%	19.95 (61.87)	5 ml OP		Loceryl	
118	TENOXICAM					
	* Tab 20 mg	15.25	100	<input checked="" type="checkbox"/>	Tilcotil	
133	AMITRIPTYLINE – Safety medicine; prescriber may determine dispensing frequency					
	Tab 25 mg	1.68	100	<input checked="" type="checkbox"/>	Amitrip	
	Tab 50 mg	2.82	100	<input checked="" type="checkbox"/>	Amitrip	
207	PHARMACY SERVICES – May only be claimed once per patient.					
	* Brand switch fee	4.33	1 fee	<input checked="" type="checkbox"/>	BSF Omnitrope	
	a) The Pharmacode for BSF Omnitrope is 2472198					

Effective 1 July 2015

83	TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist					
	Inj 250 mg per ml, 4 ml	86.00	1	<input checked="" type="checkbox"/>	Reandron 1000	
	Note – this is the delisting of Reandron 1000 in the ampoule presentation (Pharmacode 2265524). A vial presentation will be listed 1 January 2015.					

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price)	\$	Per	Brand or Generic Mnfr
				✓ fully subsidised

Items to be Delisted – effective 1 July 2015 (continued)

95	CEFUROXIME SODIUM Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement.....	6.96	5	✓ m-Cefuroxime
	Waiver by endorsement must state that the prescription is for dialysis or cystic fibrosis patient.			
143	HALOPERIDOL – Safety medicine; prescriber may determine dispensing frequency Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO	21.55	10	✓ Haloperidol - MercuryPharma S29

Index

Pharmaceuticals and brands

A	
Allopurinol.....	30
Amitrip.....	30, 33
Amitriptyline.....	30, 33
Amorolfine	29, 33
Apo-Allopurinol	30
Arrow-Citalopram.....	28
B	
Betamethasone valerate with clioquinol.....	31
Betnovate-C	31
Bisoprolol fumarate	25, 29
Bosvate	25, 29
BSF Omnitrope.....	23, 33
C	
Carbimazole	25
Cefuroxime sodium	34
Citalopram hydrobromide	28
Clexane.....	24
Coversyl	31
Cyproterone acetate with ethynodiol dienoate	30
D	
Dalteparin sodium	24
Danthron with poloxamer.....	31
Desferrioxamine mesylate	26, 30
Diazepam.....	25, 30
Docusate sodium	29, 33
Dorzolamide hydrochloride	30
DP Lotn HC.....	25
Dr Reddy's Pramipexole	31
E	
Enoxaparin sodium.....	24
Ethics Paracetamol	31
Ethinodiol dienoate with desogestrel	29
F	
Finasteride	30
Fluarix.....	27
Foban	29, 33
Fortisip	32
Fragmin	24
Fusidic acid.....	29, 33
G	
Ganciclovir.....	23
Genotropin	31
Ginet 84.....	30
H	
Haloperidol	34
Haloperidol - MercuryPharma.....	34
Hydrocortisone and paraffin liquid and lanolin	25
Hydrocortisone with wool fat and mineral oil.....	25
Hyoscine hydrobromide	26, 30
I	
Imatinib-AFT	26
Imatinib mesilate	26
Influenza vaccine.....	27
Influvac.....	27
K	
Kogenate FS.....	31
L	
Laxofast 50.....	29, 33
Laxofast 120.....	29, 33
Loceryl	29, 33
Losartan potassium.....	29, 33
Lostaar	29, 33
M	
Magnesium sulphate	31
Marvelon 28.....	29
m-Cefuroxime	34
Mercilon 28	29
Miconazole nitrate	29
N	
Naloxone hydrochloride.....	26, 30
Neo-Mercazole.....	25
O	
Octocog alfa [recombinant factor viii]	31
Omnitrope.....	25
Oral feed (powder)	32
Oxycodone hydrochloride	32
Oxydone BNM	32
P	
Paracetamol	31
Paracetamol + Codeine (Relieve).....	30
Paracetamol with codeine	30
Perindopril	31
Pharmacy services.....	23, 33
Pinorax Forte.....	31
Pramipexole hydrochloride	25, 31
Promethazine hydrochloride	26, 30
R	
Ramipex	25
Reandron 1000	23, 33
S	
Sertraline	32
Solifenacin succinate	30
Somatropin (genotropin)	31
Somatropin (omnitrope)	25
Standard supplements.....	26
T	
Tenoxicam.....	30, 33
Testosterone undecanoate.....	23, 33
Tilcotil.....	30, 33
Trusopt	30

Index

Pharmaceuticals and brands

V		Z	
Vesicare.....	30	Zoloft.....	32
Virgan.....	23		

New Zealand
Permit No. 478

Permit 

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Freephone Information line (9am-5pm weekdays) 0800 66 00 50

ISSN 1172-9376 (Print)

ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.



New Zealand Government

PHARMAC
Pharmaceutical Management Agency

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand